Jenna Gregory (MD, PhD)

Dr. Gregory is developing an early warning system for neurodegenerative disease, focused on detecting pathology long before clinical symptoms appear. Her work with RNA aptamers identifies TDP-43 pathology with unprecedented sensitivity, and her skin biopsy research has demonstrated detectable pathology up to 26.5 years before diagnosis, opening the possibility of transforming presymptomatic monitoring from a source of uncertainty into a strategy for timely intervention. Her research is driven by a central question: not just what is happening in disease progression, but when it can first be detected and acted upon.
Beyond her own laboratory, Dr. Gregory serves as a co-investigator on a research program using synchrotron X-ray fluorescence imaging at the European Synchrotron Radiation Facility to investigate the C9orf72 paradox. Her team leads the pathomolecular profiling and low-field MRI platform aimed at translating nanoscale metal–aggregate signatures into a scalable diagnostic tool. She also builds and leads large presymptomatic research cohorts designed to enable early-stage disease discovery and intervention trials. As a practising pathologist and clinical lead for a major tissue bank, she integrates patient-derived biospecimens, clinical phenotyping, and molecular pathology to create resources that support collaborative discovery across the ALS research community.